Table 3 Univariate and multivariate overall survival analyses

EGFR positive vs EGFR negative

0.91 (0.66 to 1.16)

.464

Age >65 vs ≤65

1.04 (0.80 to 1.29)

.747

ECOG performance status 2–3 vs 0-1

2.13 (1.66 to 2.60)

.002

Therapy with 2- drug vs 3- drug combination

0.82 (0.58 to 1.07)

.117

gastroesophageal junction vs Stomach

0.69 (0.40 to 0.97)

.009

recurrent disease vs Stage IV at diagnosis

0.84 (0.50 to 1.18)

.326

Male vs female

0.92 (0.67 to 1.17)

.512

Liver metastasis, yes vs no

1.19 (0.95 to 1.44)

.163

Peritoneal metastasis, yes vs no

1.26 (1.00 to 1.52)

.079

Intestinal vs diffuse/mixed

0.90 (0.63 to 1.16)

.43

Multivariate Overall Survival Analysis

Characteristic

Hazard ratio (95% CI)

P- value

EGFR positive vs EGFR negative

0.85 (0.57 to 1.13)

.247

Age >65 vs ≤65

1.16 (0.88 to 1.45)

.299

Therapy with 2- drug vs 3- drug combination

0.71 (0.39 to 0.97)

.033

gastroesophageal junction vs Stomach

0.78 (0.43 to 1.14)

.176

recurrent disease vs Stage IV at diagnosis

0.71 (0.33 to 1.10)

.087

Male vs female

1.01 (0.71 to 1.30)

.959

Intestinal vs. diffuse/mixed

0.9 (0.59 to 1.22)

.517